Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clomethiazole is a sedative and hypnotic drug structurally related to thiamine (vitamin B1) but pharmacologically distinct from benzodiazepines and barbiturates. It acts as a positive allosteric modulator at the barbiturate/picrotoxin site of the GABAA receptor, enhancing the action of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system. This results in anxiolytic, anticonvulsant, sedative, and hypnotic effects. Clomethiazole is primarily used for treating and preventing symptoms of acute alcohol withdrawal syndrome, agitation or restlessness in elderly patients (including those with dementia), short-term severe insomnia in elderly patients, and has also been used for neuroprotection in stroke research. The drug is approved under various brand names such as Heminevrin[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clomethiazole.